# A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

> **NCT00934375** · PHASE4 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 145 (actual)

## Conditions studied

- Mild Cognitive Impairment

## Interventions

- **DRUG:** Aricept (donepezil hydrochloride)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00934375
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2014-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00934375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00934375, "A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00934375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*